n the past 150 years artificial methods of passive immunity have been developed

n the past 150 years artificial methods of passive immunity have been developed by transferring immune substances (antibodies) from human and non-human blood to help fight infections, venoms and toxins, and cancer. Historically, it was observed that human and non-human animals that showed a high survival rate from infection might hold substances in their blood that protect them. It was discovered that blood carries immune proteins termed antibodies (Ab) or immunoglobulins (Ig) that are produced for specific infections (antigens) and can be isolated and transferred to others for protection. Passive immunity refers to immune substances that are passed from an external source to an infected individual to protect against infection or other antigens. Passive immunity can be naturally acquired such as through breast milk to a neonate or via placental transfer. Artificial acquired passive immunity is administering antibody products (antisera or antitoxin) to infected individuals to help fight infection.
Choose one antibody therapy from the list that follows and complete the assignment closely following the Infection assignment instructions.
• Casirivimab or Imdevimab or Sotrovimab (SARS-CoV-2)
• Atoltivimab or Maftivimab or Odesivimab (Ebola)
• Palivizumab or Felvizumab or Motavizumab (RSV)
• Bezlotoxumab or Actoxumab (Cdiff)
• Raxibacumab (anthrax)
• Rafivirumab or HRIG (rabies)
• Regavirumab (CMV)
• Suvratoxumab (S aureus)
• Urtoxazumab (E coli toxin)
• TIG (tetanus)
• BAT (botulism)
• Diphtheria antitoxin (DAT)
• Hepatitis B immunoglobulin (HBIG)
• Cytomegalovirus IVIG
• Vaccinia immune globulin (VIG)
It is required that you review spelling and grammar before submitting your work. You are allowed 2 submissions before the due date. The first submission will include a plagiarism analysis and may have instructor comments. Second submissions (resubmission) will not be counted (graded) after the due date. Late submissions will result in a decrease in 20% of the graded points per day late.
Requirements to receive full points for each short answer:
•
o Use the therapy as the header or title then include each question before each response.
o A minimum of two citations are required in correct CSE format. See the Module on Citations.
o A complete narrative for each response is required for full points.
o
You must include each section title followed by your responses.
1) Antibody or antisera source and target antigen
a. Describe the source of the antibody or antisera product and identify the antibody classes in the product.
b. Identify and discuss the specific target such as viral spikes or bacteria toxins and mechanism of action (MOA) that the antibody or antisera is designed to neutralize.
2) Clinical use
a. What condition or symptoms must the patient have to receive this treatment?
b. Discuss when and how is the antibody/antisera product administered?
Rubric
Passive immunization assignment (1)
Passive immunization assignment (1)
Criteria Ratings Pts
This criterion is linked to a Learning OutcomeAntibody or antisera source and target antigen
a. Describe the source of the antibody or antisera product and the antibody class.
b. Identify and discuss the specific microbe or toxin that the antibody or antisera is designed to neutralize. 6 to >0.0 pts
Full points 0 pts
No points
Plagiarism or unclear or missing work.
6 pts
This criterion is linked to a Learning OutcomeClinical use
a. What condition or symptoms must the patient have for this treatment?
b. Discuss when and how is the antibody/antisera product administered? 6 to >0.0 pts
Full Points 0 pts
No points
Plagiarism or unclear or missing work.
6 pts
This criterion is linked to a Learning OutcomeCitations: in correct CSE format for each source. 2 to >0.0 pts
Full points 0 pts
No points
Incorrect CSE format or missing citations
2 pts
Total Points: 14
Please use references from the last 5 years that are peer reviewed